ATE517898T1 - Verfahren zur herstellung von triazolsubstituierten azaindoloxoessigsäurepiperazinderivaten und dabei hergestellte neue salzformen - Google Patents
Verfahren zur herstellung von triazolsubstituierten azaindoloxoessigsäurepiperazinderivaten und dabei hergestellte neue salzformenInfo
- Publication number
- ATE517898T1 ATE517898T1 AT06785355T AT06785355T ATE517898T1 AT E517898 T1 ATE517898 T1 AT E517898T1 AT 06785355 T AT06785355 T AT 06785355T AT 06785355 T AT06785355 T AT 06785355T AT E517898 T1 ATE517898 T1 AT E517898T1
- Authority
- AT
- Austria
- Prior art keywords
- azaindoloxoacetic
- substituted
- salt forms
- produced therefrom
- piperazine derivatives
- Prior art date
Links
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical class C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000003839 salts Chemical group 0.000 title 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
- C07C311/49—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/26—Radicals substituted by halogen atoms or nitro radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69300405P | 2005-06-22 | 2005-06-22 | |
| PCT/US2006/024335 WO2007002308A2 (en) | 2005-06-22 | 2006-06-21 | Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE517898T1 true ATE517898T1 (de) | 2011-08-15 |
Family
ID=37460063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06785355T ATE517898T1 (de) | 2005-06-22 | 2006-06-21 | Verfahren zur herstellung von triazolsubstituierten azaindoloxoessigsäurepiperazinderivaten und dabei hergestellte neue salzformen |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7601715B2 (de) |
| EP (1) | EP1907389B1 (de) |
| JP (1) | JP5010593B2 (de) |
| CN (1) | CN101243085A (de) |
| AR (1) | AR055801A1 (de) |
| AT (1) | ATE517898T1 (de) |
| ES (1) | ES2368788T3 (de) |
| NO (1) | NO341136B1 (de) |
| PE (1) | PE20070122A1 (de) |
| TW (1) | TW200740807A (de) |
| WO (1) | WO2007002308A2 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7601715B2 (en) * | 2005-06-22 | 2009-10-13 | Bristol-Myers Squibb Company | Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein |
| US7598380B2 (en) * | 2005-08-03 | 2009-10-06 | Bristol-Myers Squibb Company | Method of preparation of azaindole derivatives |
| CA2730253A1 (en) * | 2008-07-08 | 2010-01-14 | Alphonso Higuera | Novel crystalline form of 2-[4-(4-fluoro-benzyl)-piperidine-1-yl]-2-oxo-n-(2-oxo-2,3-dihydro-benzoxazol-6-yl)-acetamide |
| HRP20120441T1 (hr) * | 2008-09-04 | 2012-06-30 | Bristol-Myers Squibb Company | Stabilna farmaceutska smjesa za optimiziranu dopremu inhibitora prianjanja hiv-a |
| KR20130012072A (ko) | 2010-03-31 | 2013-01-31 | 액테리온 파마슈티칼 리미티드 | 항박테리아성 이소퀴놀린-３-일우레아 유도체 |
| AR080908A1 (es) * | 2010-04-16 | 2012-05-16 | Novartis Ag | Formulaciones de un piridazin -bipirazinilo |
| US20110263701A1 (en) * | 2010-04-21 | 2011-10-27 | Sigal Blau | Gabapentin enacarbil compositions |
| CN102372707B (zh) * | 2010-08-16 | 2015-08-19 | 上海药明康德新药开发有限公司 | 6-甲基-4-溴-1,6-二氢吡咯[2,3-c]吡啶-7-酮的合成方法 |
| SG191841A1 (en) | 2011-01-31 | 2013-08-30 | Bristol Myers Squibb Co | Methods of making hiv attachment inhibitor prodrug compound and intermediates |
| CN102993109A (zh) * | 2012-12-03 | 2013-03-27 | 浙江工业大学 | 一种脒化合物的制备方法 |
| EP3077396B1 (de) * | 2013-12-05 | 2021-04-21 | F. Hoffmann-La Roche AG | Synthese von trans-8-chlor-5-methyl-1-[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]amidgruppen und kristalline formen davon |
| AR099677A1 (es) | 2014-03-07 | 2016-08-10 | Sumitomo Chemical Co | Compuesto heterocíclico fusionado y su uso para el control de plagas |
| CN108863917A (zh) * | 2017-05-16 | 2018-11-23 | 穆云 | 一种2,5-二甲氧基吡啶的制备方法 |
| US12157753B2 (en) | 2019-01-17 | 2024-12-03 | ViiV Healthcare UK (No.4) Limited | Process for preparing Fostemsavir |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3545461B2 (ja) * | 1993-09-10 | 2004-07-21 | エーザイ株式会社 | 二環式ヘテロ環含有スルホンアミド誘導体 |
| ZA949293B (en) | 1993-12-08 | 1995-08-17 | Nihon Nohyaku Co Ltd | Hydrazine derivatives and uses thereof |
| US6476034B2 (en) * | 2000-02-22 | 2002-11-05 | Bristol-Myers Squibb Company | Antiviral azaindole derivatives |
| US20020061892A1 (en) | 2000-02-22 | 2002-05-23 | Tao Wang | Antiviral azaindole derivatives |
| US20040110785A1 (en) * | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US20030207910A1 (en) | 2001-02-02 | 2003-11-06 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| SK287900B6 (sk) | 2001-02-02 | 2012-03-02 | Bristol-Myers Squibb Company | Substituted azaindolexoacetic piperazine derivatives and pharmaceutical composition containing thereof |
| US20040063744A1 (en) | 2002-05-28 | 2004-04-01 | Tao Wang | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides |
| US7745625B2 (en) * | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| US20060100432A1 (en) * | 2004-11-09 | 2006-05-11 | Matiskella John D | Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione |
| US7601715B2 (en) * | 2005-06-22 | 2009-10-13 | Bristol-Myers Squibb Company | Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein |
-
2006
- 2006-06-19 US US11/455,338 patent/US7601715B2/en active Active
- 2006-06-21 AT AT06785355T patent/ATE517898T1/de not_active IP Right Cessation
- 2006-06-21 ES ES06785355T patent/ES2368788T3/es active Active
- 2006-06-21 EP EP06785355A patent/EP1907389B1/de active Active
- 2006-06-21 WO PCT/US2006/024335 patent/WO2007002308A2/en not_active Ceased
- 2006-06-21 AR ARP060102666A patent/AR055801A1/es unknown
- 2006-06-21 JP JP2008518395A patent/JP5010593B2/ja active Active
- 2006-06-21 CN CNA2006800304477A patent/CN101243085A/zh active Pending
- 2006-06-22 TW TW095122521A patent/TW200740807A/zh unknown
- 2006-06-22 PE PE2006000714A patent/PE20070122A1/es not_active Application Discontinuation
-
2007
- 2007-12-20 NO NO20076575A patent/NO341136B1/no not_active IP Right Cessation
-
2009
- 2009-08-27 US US12/548,809 patent/US7968718B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| NO341136B1 (no) | 2017-08-28 |
| WO2007002308A2 (en) | 2007-01-04 |
| EP1907389A2 (de) | 2008-04-09 |
| EP1907389B1 (de) | 2011-07-27 |
| US7601715B2 (en) | 2009-10-13 |
| NO20076575L (no) | 2008-03-18 |
| US7968718B2 (en) | 2011-06-28 |
| JP2008546795A (ja) | 2008-12-25 |
| CN101243085A (zh) | 2008-08-13 |
| WO2007002308A3 (en) | 2007-07-12 |
| US20060293304A1 (en) | 2006-12-28 |
| AR055801A1 (es) | 2007-09-05 |
| JP5010593B2 (ja) | 2012-08-29 |
| ES2368788T3 (es) | 2011-11-22 |
| US20100076191A1 (en) | 2010-03-25 |
| WO2007002308A9 (en) | 2007-03-01 |
| TW200740807A (en) | 2007-11-01 |
| PE20070122A1 (es) | 2007-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602005023243D1 (de) | Verfahren zur Herstellung von Saugkernen | |
| ATE408604T1 (de) | Verfahren zur herstellung von 1-alkyl-3- phenyluracilen | |
| DE602004026576D1 (de) | Verbessertes verfahren zur herstellung vom rosuvastatin calcium salz | |
| ATE533747T1 (de) | Verfahren zur herstellung von tetrahydrochinolinderivaten | |
| ATE408609T1 (de) | Verfahren zur herstellung von n-phenylpyrazol-1- carboxamiden | |
| ATE516816T1 (de) | Verfahren zur herstellung von impfstoffen | |
| DE602005019848D1 (de) | Verfahren zur herstellung von tad- getrocknetem ti | |
| ATE462806T1 (de) | Verfahren zur herstellung von titan | |
| DE602005016292D1 (de) | Verfahren zur herstellung von glatiramer | |
| ATE489015T1 (de) | Verfahren zur herstellung von verschlüssen | |
| ATE517898T1 (de) | Verfahren zur herstellung von triazolsubstituierten azaindoloxoessigsäurepiperazinderivaten und dabei hergestellte neue salzformen | |
| ATE552250T1 (de) | Verfahren zur herstellung von duloxetin und verwandten verbindungen | |
| DE502005007762D1 (de) | Verfahren zur herstellung von zahnrädern | |
| ATE376997T1 (de) | Verfahren zur herstellung von 1,4- diphenylazetidinon-derivaten | |
| ATE452894T1 (de) | Verfahren zur herstellung von salzen von 4-ää5- ä(cyclopropylamino)carbonylü-2- methylphenylüaminoü-5-methyl-n-propylpyrroloä2, - füä1,2,4ütriazin-6-carboxamid und damit hergestellte neue stabile formen | |
| DE602006013572D1 (de) | Resistzusammensetzung und Verfahren zur Herstellung von Mustern | |
| ATE461919T1 (de) | Verfahren zur herstellung von montelukast und zwischenprodukte dafür | |
| ATE460414T1 (de) | Verfahren zur herstellung von tiotropiumsalzen | |
| ATE406372T1 (de) | Verfahren zur herstellung von 3-o-geschützten morphinonen und 3-o-geschützten morphinondienolcarboxylaten | |
| ATE444303T1 (de) | Verfahren zur herstellung von ferrisuccinylcasein | |
| ATE542533T1 (de) | Verfahren zur herstellung von isothiazol- derivaten | |
| ATE427040T1 (de) | Verfahren zur herstellung von nahrungsmitteln und so hergestelltes nahrungsmittel | |
| ATE549314T1 (de) | Verfahren zur herstellung von 4-aminochinazolinen | |
| ATE433955T1 (de) | Verfahren zur herstellung von aryl- und heteroarylalkylsulfonylhalogeniden | |
| DE602006018182D1 (de) | Verfahren zur herstellung von aralkyloxypyrrolidinderivaten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |